• Home
  • NEW DAY MEDICINE
  • 1 (87) 2026
  • 1 -1 (87) 2026 - Ibragimov I.Sh., Kasparova G.A. - OPTIMIZATION OF DIAGNOSIS OF CERVICAL CANCER RECURRENCE AT THE PRECLINICAL STAGE: THE ROLE OF INSTRUMENTAL AND IMMUNOHISTOCHEMICAL METHODS

1 -1 (87) 2026 - Ibragimov I.Sh., Kasparova G.A. - OPTIMIZATION OF DIAGNOSIS OF CERVICAL CANCER RECURRENCE AT THE PRECLINICAL STAGE: THE ROLE OF INSTRUMENTAL AND IMMUNOHISTOCHEMICAL METHODS

OPTIMIZATION OF DIAGNOSIS OF CERVICAL CANCER RECURRENCE AT THE PRECLINICAL STAGE: THE ROLE OF INSTRUMENTAL AND IMMUNOHISTOCHEMICAL METHODS

Ibragimov I.Sh. - Samarkand State Medical University

Kasparova G.A. - Samarkand State Medical University

Resume

Cervical cancer remains a major cause of morbidity and mortality among women, particularly in low- and middle-income countries like Uzbekistan. The study (2023–2025, n=87 patients post-treatment for FIGO I–III cervical cancer) aimed to optimize preclinical detection of recurrence using instrumental (colposcopy, ultrasound, MRI) and immunohistochemical (CD3+, CD20+) methods. Patients were divided into main group with recurrence (n=55, mean detection at 8.5 months) and control group without recurrence (n=32). Recurrences were predominantly local, with 52.7% <1 cm. Colposcopy showed the highest sensitivity (95% for <1 cm tumors), outperforming ultrasound and MRI; MRI provided the highest specificity (>90%). Combination of colposcopy + MRI increased accuracy to 88.5%. IHC analysis revealed significantly lower CD3+ and CD20+ lymphoid infiltration in the recurrence group, with low-density infiltrate (>50% score 1+) indicating immune suppression and serving as an independent prognostic factor. Risk factors for recurrence included large primary tumor, advanced stage, and lymph node involvement. The proposed integrated algorithm (colposcopy + IHC + MRI) achieves diagnostic accuracy up to 89.8%, enables early identification of high-risk patients, improves survival and quality of life, and is suitable for implementation in Uzbekistan’s healthcare system.

Keywords: cervical cancer recurrence, preclinical diagnosis, colposcopy, ultrasound, MRI, CD3, CD20, immunohistochemistry, immune infiltration, early detection.

First page

2

Last page

6

For citation:Ibragimov I.Sh., Kasparova G.A. - OPTIMIZATION OF DIAGNOSIS OF CERVICAL CANCER RECURRENCE AT THE PRECLINICAL STAGE: THE ROLE OF INSTRUMENTAL AND IMMUNOHISTOCHEMICAL METHODS//New Day in Medicine 1(87)2026 2-6 https://newdayworldmedicine.com/en/new_day_medicine/1-87-2026

List of References

  1. World Health Organization. Global Cancer Observatory: Cancer Today https://gco.iarc.fr/today.
  2. Ferlay J., Soerjomataram I., Dikshit R. et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 // Int. J. Cancer. 2015;136(5):359–386.
  3. Алмухамедова Б.Г. Эпидемиология рака шейки матки в Узбекистане // Бюлл. ассоц. врачей Узбекистана. 2016;4:27-29.
  4. Zhonghua F. et al. Analysis of prognostic factors and therapeutic patterns of recurrent stageⅠb-Ⅱa cervical squamous carcinoma treated with radical hysterectomy // Zhonghua Fu Chan Ke Za Zhi. 2019;54(6):399-405.
  5. Bentivegna E., Gouy S., Maulard A. et al. Oncological outcomes after fertility-sparing surgery for cervical cancer: a systematic review // Lancet Oncol. 2016;17(6):240–253.
  6. Grigsby P.W. Radiotherapy for pelvic recurrence after radical hysterectomy for cervical cancer // Radiat. Med. 2005;23(5):327-330.
  7. Kitajima K., Murakami K., Yamasaki E. et al. Performance of FDG-PET/CT for diagnosis of recurrent uterine cervical cancer // Eur. Radiol. 2008;18(10):2040–2047.
  8. Ибрагимов И.Ш. Современные подходы к диагностике рецидива рака шейки матки: магистерская диссертация. – Самарканд: СамГМУ, 2025; 110 с.
  9. Soutter W.P., Sasieni P., Panoskaltsis T. Long-term risk of invasive cervical cancer after treatment of squamous cervical intraepithelial neoplasia // Int. J. Cancer. 2006;118(8):2048–2055.
  10. Ghaem-Maghami S., Sagi S., Majeed G. et al. Incomplete excision of cervical intraepithelial neoplasia and risk of treatment failure: a meta-analysis // Lancet Oncol. 2007;8(11):985–993.
  11. Hricak H., Swift P.S., Campos Z. et al. Irradiation of the cervix uteri: value of unenhanced and contrast-enhanced MR imaging // Radiology. 1993;189(2):381-388.
  12. European Society for Medical Oncology (ESMO). Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up // Ann. Oncol. 2017;28(4):72–83.
  13. Yunxia T., Mei P., Shuhong S. et al. CD3+CD56+ natural killer T cell infiltration is increased in cervical cancer and negatively correlated with tumour progression // Biotechnol. Biotechnol. Equip. 2019;33(1):1380-1391.
  14. Shabaneh T.B., Molodtsov A.K., Steinberg S.M. et al. Oncogenic BRAF(V600E) governs regulatory T-cell recruitment during melanoma tumorigenesis // Cancer Res. 2018;78(17):5038–5049.
  15. Kocken M., Helmerhorst T.J.M., Berkhof J. et al. Risk of recurrent high-grade cervical intraepithelial neoplasia after successful treatment: a long-term multi-cohort study // Lancet Oncol. 2011;12(5):441-450.
  16. Dijkstra M.G., Snijders P.J., Arbyn M. et al. Cervical cancer screening: on the way to a shift from cytology to full molecular screening // Ann. Oncol. 2014;25(5):927-935.

    file

    download